The FDA enforcement report dated 14 October lists Class II recalls of several compounded incretin products, including tirzepatide and semaglutide mixed with cyanocobalamin. The firm attributes the sterility concern to formulation with bacteriostatic water and to processing equipment.
Compounded versions of these drugs carry dosing as well as sterility risks, because concentrations and diluents vary. Prescribers asked about such products can point patients towards approved formulations.
- Recalled products include tirzepatide and semaglutide combined with cyanocobalamin.
- The stated reason is lack of assurance of sterility linked to formulation and equipment.
- The named compounder is Carolina Infusion; recalls are ongoing.
- These are US products; whether any reached India is not known.
Why it matters
Compounded products sit outside the manufacturing controls of licensed pens, and patients rarely volunteer where theirs came from.
Don't overread it
A Class II recall reflects a possible manufacturing problem; it does not establish that patients were harmed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free